In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

Takeda and Seattle Genetics are closing in on a new front-line use for their Adcetris in classical Hodgkin lymphoma after a successful late-stage trial. The positive results from the phase 3 ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

WearOptimo, a healthcare technology company developing next-generation Microwearable sensors for hydration and biomarker monitoring, today introduced its Advisory Board comprised of globally ...

In 2025, seniors will pay less for 64 medications if they get them through Medicare Part B, which covers outpatient care, ...